The promise and perils of biomarker testing in gynecologic cancers

•Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes.•Overcoming barriers to biomarker testing utilization is essential for equitable access and optimal care for all patients.•Implementing policy change, clinical pathways, and educ...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Gynecologic oncology Ročník 201; s. 53 - 55
Hlavní autoři:	Fitch, Katherine C., Previs, Rebecca A., Moss, Haley A.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.10.2025
Témata:	Hematology, Oncology, and Palliative Medicine Obstetrics and Gynecology
ISSN:	0090-8258, 1095-6859, 1095-6859
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	•Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes.•Overcoming barriers to biomarker testing utilization is essential for equitable access and optimal care for all patients.•Implementing policy change, clinical pathways, and educational programs can enhance the effective use of biomarker testing.
Bibliografie:	SourceType-Scholarly Journals-1 content type line 23 ObjectType-Editorial-2 ObjectType-Commentary-1
ISSN:	0090-8258 1095-6859 1095-6859
DOI:	10.1016/j.ygyno.2025.07.019